Arisgen

Arisgen has a unique formulation technology that will enable peptide drugs such as insulin currently only delivered by injection to be given orally.

  • Stage Concept Only
  • Industry Biotechnology
  • Location Geneva, Switzerland
  • Currency CHF
  • Founded 2008
  • Employees 6
  • Website arisgen.com

Company Summary

Arisgen is a drug delivery company with a proprietary formulation technology that enables delivery of therapeutic peptides via oral or sub-lingual routes. Arisgen is developing novel products for the treatment of metabolic diseases and oncology. Projects are completing pre-clinical PoC and toxicological assessment with the aim of entering clinical studies in 2015.

Team

  • Andy Parker
    CEO

    20 years experience in drug discovery and development. Previous positions include VP, Head of Exploratory Projects, Shre Pharmaceuticals; VP, Head of Research, Opsona Therapeutics; Head of In Vitro Pharmacology, Respiratory & Inflammation Research, AstraZeneca

Starting a startup?

Join the world's largest startup network for guidance, tools, and fundraising opportunities.

Get Started for Free